Generex Biotechnology Corp. (GNBT)
| Market Cap | 23.77M |
| Revenue (ttm) | 692,762 |
| Net Income (ttm) | n/a |
| Shares Out | 120.82M |
| EPS (ttm) | -0.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 221,289 |
| Open | 0.1749 |
| Previous Close | 0.2010 |
| Day's Range | 0.1714 - 0.2070 |
| 52-Week Range | 0.1650 - 0.5000 |
| Beta | -2.91 |
| Analysts | n/a |
| Price Target | 6.00 (+2,889.5%) |
| Est. Earnings Date | n/a |
About GNBT
Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, i...
News
NuGenerex Immuno-Oncology Secures $535 Million Valuation from World-Class Independent Valuation & Appraisal Firm
MIRAMAR, Fla., June 22, 2021 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO – www.nugenerexio.com), a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or th...
Generex Biotechnology Subsidiary NuGenHealth Contracts with Westside Medicine & Cardiology, Inc. to Provide Remote Pa...
MIRAMAR, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company wit...
Generex Posts Recording of May 6 Shareholder Conference Call Highlighting its Ii-Key COVID Complete Vaccine™ and its ...
MIRAMAR, Fla., May 10, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company wit...
Generex Biotechnology Subsidiary NuGenHealth Contracts with Florida Health Care Associates to Provide Remote Patient ...
MIRAMAR, Fla., May 06, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company wit...
Generex Provides Clarification on Its Ii-Key COVID-19 Complete Vaccine China Partnership Agreement
MIRAMAR, Fla., May 05, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company wit...
Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Thursday May 6, 2021 at...
MIRAMAR, Fla., May 04, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company wit...
Generex Biotechnology Subsidiary Olaregen Therapeutix Announces Agreement with Nexgen Medical for Distribution of Exc...
MIRAMAR, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) subsidiary Olaregen Therapeutix today announced that the company has executed a Distribut...
NuGenerex Immuno-Oncology Submits Protocol, Data, and Manufacturing Information to FDA in Advance of the IND Submission
MIRAMAR, Fla., April 12, 2021 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO – www.nugenerexio.com), a subsidiary of Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) (“Generex” o...
Last Chance for Children is Proud to Announce its Partnership with Generex Biotechnology & NuGenerex Immuno-Oncology ...
NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- Last Chance for Children's (LCFC) Mission is to help save children's lives anywhere in the world. Due to the COVID-19 pandemic we are now focusing our effort...
Generex Biotechnology Announces Shareholder Conference Call Scheduled for Thursday May 6, 2021
MIRAMAR, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB: GNBT) (“Generex or the “Company”), an innovative and integrated healthcare holding company with end-to-end sol...
Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Complete Vaccine™ Development Program
MIRAMAR, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has compl...
Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Friday February 5, 2021...
The access information for the investor conference call is as follows: Domestic US/Canada - 1-(866) 342-8588Direct Toll / International - 1-(203) 518-9865 Program Title: Generex Biotechnology Conference...
Generex Biotechnology Announces Investor Conference Call Scheduled for Friday February 5, 2021 at 9:00 AM
MIRAMAR, Fla., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it will hold an investor conference call on Friday February 5, 2021...
Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Tradema...
MIRAMAR, Fla., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that its majority owned pub...
Generex and NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Exclusive Distribu...
MIRAMAR, Fla., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) and subsidiary NuGenerex Immuno-Oncology to...
Generex signs Worldwide Licensing Deal with China Partners on the Development of an Ii-Key-H1 Swine Influenza Vaccine
MIRAMAR, Fla., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has...
Generex Inks $50 Million Licensing Deal with China Partners on the Cooperative Development of the Ii-Key Vaccine Plat...
MIRAMAR, Fla., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has...
Generex Announces the Signing of a Framework Agreement with The China CDC, Beijing Guoxin Haixiang Equity Investment ...
MIRAMAR, Fla., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has signed...
NuGenerex Immuno-Oncology Announces the Launch of a New Corporate Website
MIRAMAR, Fla., Nov. 03, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO), a subsidiary of Generex Biotechnology Corporation ( www.gen erex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/G...
Generex Sees Way Forward With Long-Lasting Covid-19 Vaccine
Ii-Key technology is safe, and in a breast cancer trial 10 years out, still effective. GNBT is negotiating contracts covering these areas: Malaysia, New Zealand, Australia, Southeast Asia, Singapore, So...
Generex Subsidiary NuGenerex Immuno-Oncology Announces Appointment of Dr. Tamera Coyne-Beasley to the Scientific Advi...
-Dr. Tamera Coyne-Beasley, MD, MPH, FAAP, FSAHM is the Derrol Dawkins, MD Endowed Chair in Adolescent Medicine at Children's of Alabama, Professor of Pediatrics and Internal Medicine, Director of the Un...
Generex Subsidiary NuGenerex Immuno-Oncology Announces Publication of a Review Article on Cancer Vaccines Highlightin...
Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design
Generex Biotechnology Announces Corporate Update and Investor Conference Call: NuGenerex Immuno-Oncology on Thursday ...
MIRAMAR, Fla., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced call-in details for tomorrow’s investor conference call on Thursday Octo...
NuGenerex Immuno-Oncology Announces Closing of a Licensing & Distribution Agreement with Bintai Kinden to Advance the...
MIRAMAR, Fla., Oct. 07, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO), a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/...
Generex Subsidiary NuGenerex Immuno-Oncology Announces World Class Scientific Advisory Board Appointments for its COV...
MIRAMAR, Fla., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has formed...